company background image
BNTC

Benitec Biopharma NasdaqCM:BNTC Stock Report

Last Price

US$1.00

Market Cap

US$8.2m

7D

-7.2%

1Y

-77.8%

Updated

26 May, 2022

Data

Company Financials +
BNTC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

BNTC Stock Overview

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines.

Benitec Biopharma Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Benitec Biopharma
Historical stock prices
Current Share PriceUS$1.00
52 Week HighUS$5.07
52 Week LowUS$0.90
Beta1.58
1 Month Change-46.97%
3 Month Change-57.35%
1 Year Change-77.83%
3 Year Change-95.82%
5 Year Change-97.07%
Change since IPO-99.71%

Recent News & Updates

Jan 13
We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate

We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Sep 30
We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully

We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

BNTCUS BiotechsUS Market
7D-7.2%0.4%1.0%
1Y-77.8%-22.1%-15.1%

Return vs Industry: BNTC underperformed the US Biotechs industry which returned -22.1% over the past year.

Return vs Market: BNTC underperformed the US Market which returned -15.1% over the past year.

Price Volatility

Is BNTC's price volatile compared to industry and market?
BNTC volatility
BNTC Average Weekly Movement11.8%
Biotechs Industry Average Movement12.4%
Market Average Movement7.8%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market2.9%

Stable Share Price: BNTC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: BNTC's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199514Jerel Bankshttps://benitec.com

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection.

Benitec Biopharma Fundamentals Summary

How do Benitec Biopharma's earnings and revenue compare to its market cap?
BNTC fundamental statistics
Market CapUS$8.19m
Earnings (TTM)-US$17.14m
Revenue (TTM)US$75.00k

109.3x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BNTC income statement (TTM)
RevenueUS$75.00k
Cost of RevenueUS$1.00k
Gross ProfitUS$74.00k
Other ExpensesUS$17.22m
Earnings-US$17.14m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.10
Gross Margin98.67%
Net Profit Margin-22,858.67%
Debt/Equity Ratio0%

How did BNTC perform over the long term?

See historical performance and comparison

Valuation

Is Benitec Biopharma undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


1.09x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BNTC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BNTC's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: BNTC is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Biotechs industry average.

PE vs Market: BNTC is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BNTC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BNTC is good value based on its Price-To-Book Ratio (1.1x) compared to the US Biotechs industry average (1.4x).


Future Growth

How is Benitec Biopharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-25.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BNTC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BNTC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BNTC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BNTC's revenue is expected to decline over the next 3 years (-73.1% per year).

High Growth Revenue: BNTC's revenue is forecast to decline over the next 3 years (-73.1% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BNTC's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Benitec Biopharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-29.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BNTC is currently unprofitable.

Growing Profit Margin: BNTC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BNTC is unprofitable, and losses have increased over the past 5 years at a rate of 29.1% per year.

Accelerating Growth: Unable to compare BNTC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BNTC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: BNTC has a negative Return on Equity (-227.98%), as it is currently unprofitable.


Financial Health

How is Benitec Biopharma's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BNTC's short term assets ($8.8M) exceed its short term liabilities ($1.9M).

Long Term Liabilities: BNTC's short term assets ($8.8M) exceed its long term liabilities ($635.0K).


Debt to Equity History and Analysis

Debt Level: BNTC is debt free.

Reducing Debt: BNTC has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BNTC has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BNTC has less than a year of cash runway if free cash flow continues to grow at historical rates of 0.5% each year.


Dividend

What is Benitec Biopharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BNTC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BNTC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BNTC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BNTC's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BNTC has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.8yrs

Average management tenure


CEO

Jerel Banks (46 yo)

3.92yrs

Tenure

US$1,403,063

Compensation

Dr. Jerel A. Banks, Ph D., M.D. has been the Chief Executive Officer of Benitec Biopharma Inc. since June 26, 2018. Dr. Banks serves as the Executive Chairman of the Board at Benitec Biopharma Inc. since O...


CEO Compensation Analysis

Compensation vs Market: Jerel's total compensation ($USD1.40M) is above average for companies of similar size in the US market ($USD771.12K).

Compensation vs Earnings: Jerel's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: BNTC's management team is seasoned and experienced (5.8 years average tenure).


Board Members

Experienced Board: BNTC's board of directors are considered experienced (6.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4%.


Top Shareholders

Company Information

Benitec Biopharma Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Benitec Biopharma Inc.
  • Ticker: BNTC
  • Exchange: NasdaqCM
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$8.190m
  • Shares outstanding: 8.17m
  • Website: https://benitec.com

Number of Employees


Location

  • Benitec Biopharma Inc.
  • 3940 Trust Way
  • Hayward
  • California
  • 94545
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/26 00:00
End of Day Share Price2022/05/26 00:00
Earnings2022/03/31
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.